Form 13-F position report

ITERUM THERAPEUTICS LTD

Reported by MORGAN STANLEY

ITRM CUSIP G6333L101 Manager CIK 0000895421

Reported 221,207 shares, down 3,610 (1.6%) from the prior quarter.

Reported value -45.0%; share count -1.6% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 221,207 Quarter-end amount reported
Reported value $44,000 Fair value at quarter end
Consecutive quarters held 17 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 75000
2022-03-31 80000
2022-06-30 44000
2022-09-30 16000
2022-09-30 0
2022-12-31 7131
2023-03-31 13948
2023-06-30 14927
2023-09-30 11174
2023-12-31 10794
2024-03-31 8438
2024-06-30 6273
2024-09-30 5972
2024-12-31 20760
2025-03-31 7962
2025-06-30 9326
2025-09-30 5771
2025-12-31 1914
2026-03-31 471
2026-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ITERUM THERAPEUTICS LTD held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Reduced 0 -15,713 (-100.0%) 0 $0 2026-08-13
Q1 2026 Added 15,713 +10,000 (175.0%) < 0.01% $471 2026-05-15
Q4 2025 Reduced 5,713 -2,900 (-33.7%) < 0.01% $1,914 2026-02-13
Q3 2025 Reduced 8,613 -760 (-8.1%) < 0.01% $5,771 2025-11-14
Q2 2025 Added 9,373 +2,900 (44.8%) < 0.01% $9,326 2025-08-15
Q1 2025 Reduced 6,473 -5,256 (-44.8%) < 0.01% $7,962 2025-05-15
Q4 2024 Added 11,729 +6,250 (114.1%) < 0.01% $20,760 2025-02-14
Q3 2024 Unchanged 5,479 0 (0.0%) < 0.01% $5,972 2024-11-14
Q2 2024 Unchanged 5,479 0 (0.0%) < 0.01% $6,273 2024-08-14
Q1 2024 Unchanged 5,479 0 (0.0%) < 0.01% $8,438 2024-05-15
Q4 2023 Reduced 5,479 -8,471 (-60.7%) < 0.01% $10,794 2024-02-13
Q3 2023 Unchanged 13,950 0 (0.0%) < 0.01% $11,174 2023-11-15
Q2 2023 Unchanged 13,950 0 (0.0%) < 0.01% $14,927 2023-08-14
Q1 2023 Added 13,950 +5,460 (64.3%) < 0.01% $13,948 2023-05-15
Q4 2022 Reduced 8,490 -1,157 (-12.0%) < 0.01% $7,131 2023-02-14
Q3 2022 Reduced 0 -221,207 (-100.0%) 0 $0 2022-11-14
Q3 2022 New 9,647 +9,647 (0.0%) < 0.01% $16,000 2022-11-14
Q2 2022 Reduced 221,207 -3,610 (-1.6%) < 0.01% $44,000 2022-08-15
Q1 2022 Added 224,817 +33,010 (17.2%) < 0.01% $80,000 2022-05-13
Q4 2021 Reduced 191,807 -263,190 (-57.8%) < 0.01% $75,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

47 managers reported ITERUM THERAPEUTICS LTD for Q2 2022.

Managers reporting ITERUM THERAPEUTICS LTD in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Canaan Partners X LLC Unchanged 1,733,170 0 0.6% $346,000 11 qtrs
New Leaf Venture Partners L L C Unchanged 1,456,303 0 0.19% $292,000 17 qtrs
IFP Advisors Inc Unchanged 6,000 0 < 0.01% $72,000 2 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 323,300 +215,200 < 0.01% $65,000 7 qtrs
The Goldman Sachs Group Inc New 304,684 +304,684 < 0.01% $61,000 1 qtr
GSA CAPITAL PARTNERS LLP New 304,684 +304,684 < 0.01% $61,000 1 qtr
FRANKLIN RESOURCES INC Reduced 258,778 -125,422 < 0.01% $52,000 4 qtrs
MORGAN STANLEY This report Reduced 221,207 -3,610 < 0.01% $44,000 17 qtrs
Krilogy Financial LLC New 200,000 +200,000 < 0.01% $40,000 1 qtr
GRIMES & COMPANY INC Added 179,396 +3,120 < 0.01% $36,000 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
SHS

Voting authority reported

Sole
220,957
Shared
0
None
250

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.